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ABNORMAL UTERINE BLEEDING
BACKGROUND
 Affects 14-25% of reproductive-aged women in the US
 Etiology can be structural and non-structural
PALM: polyps, adenomyosis, leiomyomas, 
malignancy/neoplasia
COEIN: coagulopathy, ovulatory dysfunction, endometrial 
disorders, iatrogenic, not otherwise classified
 Unknown how the space environment affects AUB
 Simulated microgravity (hind-limb unloading) affects estrous 
cycling
Bed rest studies have not affected the menstrual cycle
ABNORMAL UTERINE BLEEDING
PRE-FLIGHT CONSIDERATIONS - STRUCTURAL
 Pre-flight TVUS (transvaginal US) recommended for all 
female astronauts with AUB
 Can consider diagnostic ± therapeutic hysteroscopy if any 
concern for endometrial or intramural pathology
 If polyp  polypectomy  LNG IUD
 If adenomyosis  LNG IUD vs. hysterectomy
 If leiomyomas myomectomy  LNG IUD
 If malignancy/neoplasia mgmt depends upon pathology
ABNORMAL UTERINE BLEEDING
PRE-FLIGHT CONSIDERATIONS – NON-STRUCTURAL
 Screening for PCOS, thyroid dysfunction, prolactinoma
 Screening for personal/family history of bleeding disorders
 Screening and treatment of iron deficiency
 Management of non-structural AUB: 
Progesterone-only or progesterone/estrogen therapy
 LNG IUDs are first line agents for treating new-onset AUB and 
preventing recurrence
 Screening for inherited thrombophilias
ABNORMAL UTERINE BLEEDING
PRE-FLIGHT CONSIDERATIONS – MENSTRUAL SUPPRESSION
Combined Hormonal Contraceptives (CHCs) and LNG-
IUD achieve highest rates of amenorrhea
 LNG-IUD: 
no risks/side effects of systemic estrogen
Remains efficacious for 5-7 years
Function is not dependent upon strict daily compliance
CHCs:
May be associated with less BMD loss
Can suppress ovarian cyst formation
Avoids IUD-associated migratory risks
More cumulative spaceflight experience
ABNORMAL UTERINE BLEEDING
IN-FLIGHT CONSIDERATIONS
 No perfect modality of inducing amenorrhea or preventing 
AUB in-flight
 Advanced surgical options likely unavailable 
pharmacologic management = mainstay of treatment
 CMOs should have some pre-flight training in digital pelvic 
examination
 Speculums are not currently available 
 Point-of-care lab tests may include CBC, pregnancy test
 TAUS (TVUS if available)
ABNORMAL UTERINE BLEEDING
IN-FLIGHT CONSIDERATIONS
 New-onset AUB in-flight:
 Continue LNG-IUD or current CHC
 Consider adding a burst taper of CHCs
 GnRH agonists/antagonists
 Non-hormonal pharmaceuticals that can be considered include:
 TXA: prevents fibrin/clot degradation w/o increasing VTE risk
 NSAIDs: shown to decrease duration and volume of menses
 Doxycycline: low risk adjunctive medication to hormonal modalities
 Extreme scenarios
BONE MINERAL DENSITY
PRE-FLIGHT/IN-FLIGHT CONSIDERATIONS
 Estrogen 
 Shown to be protective against cortical / cancellous BMD loss 
in microgravity analogs and spaceflight
 Evidence is inconclusive for LNG-IUD
 Recommend vitamin D and calcium supplementation
 Recommend resistive exercise
 May consider bisphosphonate
OVARIAN CYSTS
PRE-FLIGHT CONSIDERATIONS
 Ovarian cyst production is common following ovulation
 Present in 5-7% of reproductive-aged females
Most will resolve spontaneously
 Theoretically, large cysts can prompt ovarian torsion
 Pre-flight management of cyst:
Observation vs. laparoscopic management for simple cysts 
Work-up for malignancy if concern
OVARIAN CYSTS
IN-FLIGHT CONSIDERATIONS
 Acute abdominopelvic pain during flight: 
 Consider torsion
 TAUS (or TVUS if available) may be diagnostic
 Management of Torsion:
 Terrestrially: surgical emergency for preservation of ovarian tissue and 
prevention of rare but severe morbidities
 In-flight management: conservative measures including of pain control 
and management of sequelae
 Long term risks likely low
VENOUS THROMBOEMBOLISM
PRE-FLIGHT/IN-FLIGHT CONSIDERATIONS
 Risk factors during flight
 Microgravity: relative lower limb immobility
 Altered hydration status and fluid distribution – increased upper extremity 
congestion, potential for VTE
 Exogenous hormone use
Cyclical use of estrogen is associated with 4-6X risk of VTE
 Unclear risk profile with continuous suppression
 Recently reported sentinel event of VTE during flight (Marshall-Goebel 
2019)
 In-flight management of VTE is a subject of current discussion in 
operational medical group
ENDOMETRIOSIS
PRE-FLIGHT/IN-FLIGHT CONSIDERATIONS
 Endometriosis affects 10% of reproductive-aged women 
 Gold standard diagnosis: Laparoscopy 
 Therapeutic options:
Continuous CHCs
High-dose progestins
GnRH agonists/antagonists with add-back estrogen
HEALTH MAINTENANCE
PRE-FLIGHT/IN-FLIGHT CONSIDERATIONS
 Screening for STIs / Pap Smear within 12 months of flight
Chlamydia, Gonorrhea, Trichomonas, Syphilis, HSV, HIV, HPV
 HSV suppression during flight if affected, consider prophylaxis?
 HPV vaccine encouraged for all astronauts
 Early colposcopic management if necessary
HEALTH MAINTENANCE
PRE-FLIGHT/IN-FLIGHT CONSIDERATIONS
 Screening for peri-menopausal symptoms, urogynecologic symptoms, 
vulvar/vaginal dermatoses prior to flight
 Screening for family history of gynecologic/breast cancers as well as 
familial cancer syndromes (i.e BRCA, HNPCC, Cowden’s)
 Annual clinical breast exams
 Diagnostic mammograms ± US/MRI PRN starting at age 35
PREGNANCY / FERTILITY
PRE-FLIGHT-POST-FLIGHT CONSIDERATIONS
 Routine pregnancy testing with final pre-flight pregnancy 
test performed ~10 days prior to flight
 Discuss fertility desires and timing before mission assignment
Discuss age-related risks associated with advanced maternal 
age if delaying parity
 Fertility outcomes have not been robustly studied post-flight
Consider assessment of ovarian reserve and oocyte/embryo 
banking
 Discuss contraceptive modalities, the risk of pregnancy in-
flight is > 0%
AREAS OF INTEREST
PRE-FLIGHT-POST-FLIGHT CONSIDERATIONS
 Long-duration spaceflight will introduce continued and novel 
challenges for maintenance of gynecological and reproductive health
 The impact of the space environment outside of LEO of women’s health 
remains unknown
 There is a driving need for increased data collection and analysis to 
properly characterize and mitigate women’s health risks in future 
spaceflight
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